Patient Characteristics and Prescribing Patterns Associated with Sofosbuvir Treatment for Chronic HCV Infection in a Commercially Insured Population
Brent M. Tambourine, PharmD, BCPS, Arash Sadeghi, PharmD, Jianing Yang, MD, MS, Karen M. Stockl, PharmD, Heidi C. Lew, PharmD, Brian K. Solow, MD, FAAFP, Josephine N. Tran, PharmD, MS
Hepatitis C is a disease of the liver resulting from infection by the hepatitis C virus (HCV). HCV infection is blood-borne and can result in an acute illness, with severity ranging from mild (little or no symptoms) to severe (symptoms requiring hospitalization).
Taking Steps to Cure Chronic Hepatitis C Virus Infection
Anthony M. Louder, PhD, RPh, Amitabh Singh, PhD, Kim Saverno, PhD, Joseph C. Cappelleri, PhD, Aaron J. Aten, PharmD, BCPS, Andrew S. Koenig, DO, FACR, Margaret K. Pasquale, PhD
Health professionals are increasingly encouraged to involve patients in their treatment decisions, recognizing that patients are experts in terms of their preferences and have unique knowledge of their own health.
Challenges in the Assessment of Patient Preferences among RA Therapies
The new proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors can have significant budget effects, depending on the breadth of the US Food and Drug Administration (FDA)’s approved labeling. American Health & Drug Benefits asked Stephen Gorshow, MD, and James T. Kenney, RPh, MBA, to participate in a teleconference to better understand how payers are approaching the management of these agents.
Major pharmaceutical companies currently devote substantial resources to detailing activities for their major products, with estimated annual spending of $7 billion to $20 billion.
Improving Patient Outcomes and Drug Prescribing Cost-Effectiveness Through Academic Detailing
Joseph Tkacz, MS, Michael P. Ingham, MSc, Brenna L. Brady, PhD, Roxanne Meyer, PharmD, Charles Ruetsch, PhD
For many years, diseasemodifying antirheumatic drugs (DMARDs) have been the mainstay of RA treatment, reducing inflammation and preventing further joint deterioration and disease progression. In the past 15 years, biologic DMARDs have become available and have proved effective for reducing inflammation and managing the disease.
You Cannot Manage What You Cannot Measure
Optimizing Rheumatoid Arthritis Therapy: Using Objective Measures of Disease Activity to Guide Treatment
After more than 2 centuries of work, we now understand more about the cellular biology of rheumatoid arthritis, but the underlying cause of the disease remains elusive.
Closing Gaps in Health Plan Performance with Stakeholder Collaboration
Page 5 of 13
Results 41 - 50 of 122
Results 41 - 50 of 122